Innovent Biologics Inc 1801.HK

Innovent Biologics Inc. is a biopharmaceuticals company. Based in China, it develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Innovent Biologics Inc. was founded in 2011 in Suzhou, China, and it is primarily focused on local distribution and development.

Innovent Biologics Inc. is listed on the Hong Kong Stock Exchange (HKEK) and is currently listed under the ticker 1801.HK. As of 2020, the market capitalisation of 1801.HK is 83.144bn HKD. The 52-week range for the 1801.HK stock price is between 23.150 HKD to 67.200 HKD.

Innovent Biologics Inc.’s main product offerings cover a wide array of pharmaceuticals, including PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303. Its highest profile drug candidates include treatments for a wide range of cancers, Hodgkin’s lymphoma, and oesophageal cancer. More recently, the company has developed strategic collaborations with both the University of Texas MD Anderson cancer Centre and Eli Lilly & Company.

If you think 1801.HK would make a good addition to your eToro portfolio, simply add the ticker to your watch list and keep an eye on the Innovent Biologics Inc. share price.